Your search for rivaroxaban returned 152 results

Active Filters

Click on a filter below to refine your search. Remove a filter to broaden your search.

Your search for rivaroxaban returned 152 results

Sort Results:

Relevant Recent

Janssen announced that the Phase 3 trial, COMPASS, is stopping earlier than planned based on the recommendation of the study’s Independent Data Monitoring Committee (DMC), as the primary major adverse cardiovascular events (MACE) endpoint has reached its pre-specified criteria for superiority.

At the 2016 American Society of Hematology (ASH) Annual Meeting, researchers from Janssen and Bayer presented data showing that cancer patients treated with Xarelto (rivaroxaban) for blood clots had significantly fewer emergency room (ER) visits and lower healthcare costs at start of therapy vs. patients given standard treatment.

For acute major bleeding within 18 hours after factor Xa inhibitor administration, a bolus and infusion of andexanet alfa (andexanet) reduces factor Xa activity, according to a study published online in the New England Journal of Medicine. The research was published to coincide with the annual European Society of Cardiology Congress.